Skip to main navigation

Overview
Events & Presentations
News Releases
- For Global Media Only
- For U.S. Media Only
Corporate Governance
Stock
Financial & Filings

News Releases
Intended for U.S. Media Only

News Releases

Year

August 6, 2026

Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026

August 6, 2026

Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.

June 30, 2026

Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial

June 26, 2026

Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®

June 25, 2026

Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026

June 13, 2026

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

June 11, 2026

5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism

June 8, 2026

Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026

May 7, 2026

Ascendis Pharma Reports First Quarter 2026 Financial Results

May 6, 2026

New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 Years

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 25

Shareholder Tools

RSS Feeds

Email Alerts

IR Contact

Footer Corporate Menu

TransCon
About us
Pipeline
Patients
Investors & News
Contact Us

Footer Copyrights Menu

Privacy Policy
Terms of Use

Ascendis, Ascendis Pharma, Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma group

© August 2026 Ascendis Pharma